Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05834582

Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer

TNBC - Triple-Negative Breast Cancer Clinical Trial

Official title:
Neoadjuvant Fluzoparib Combined With Chemotherapy in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer: an Open, Multicenter, Cohort Trial

Clinical Trial Summary

Although many PARP inhibitors did not improve pCR in neoadjuvant studies, it is not an unchallenged conclusion that TNBC does not benefit from use of PARP inhibitors in neoadjuvant therapy.This study is an open-label, two-cohort, multicenter trial. 60 patients with germline BRCA-mutated three-negative early breast cancer are planned to be enrolled and treated with fluzoparib combined with chemotherapy according to tumor response after EC (epirubicin and cyclophosphamide) for 2 cycles.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05834582
Study type Interventional
Source The First Affiliated Hospital with Nanjing Medical University
Contact Xiaoan Liu, Professor
Phone 025-68308162
Email liuxiaoan@126.com
Status Recruiting
Phase Phase 2
Start date April 8, 2023
Completion date June 1, 2026
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05491694 - To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer Phase 2
Recruiting NCT06125080 - The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study Phase 2
Recruiting NCT05396612 - Role of the Immune Environment in Response to Therapy in Breast Cancer
Completed NCT03719326 - A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies Phase 1
Recruiting NCT04674306 - Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer Early Phase 1
Recruiting NCT06230185 - ctDNA Based MRD Testing for NAC Monitoring in TNBC
Recruiting NCT05491226 - Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation Phase 2
Withdrawn NCT05062174 - Breast Cancer BRCA1 Carriers: a Pilot Study
Recruiting NCT06059469 - PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer. Phase 2
Terminated NCT03875313 - Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03057600 - Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) Phase 2
Recruiting NCT04706962 - TH1902 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05274451 - A Study to Investigate LYL797 in Adults With Solid Tumors Phase 1
Not yet recruiting NCT04755868 - Talazoparib Maintenance Therapy in Triple-negative Breast Cancer Phase 2
Recruiting NCT01042379 - I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Phase 2
Recruiting NCT05848739 - A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors Phase 1
Not yet recruiting NCT06358573 - Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK Phase 2
Active, not recruiting NCT05451849 - A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer Phase 1/Phase 2
Recruiting NCT05914961 - Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer
Completed NCT05390710 - PhI to Solid Tumors and PhII to Locally Advanced or mTNBC Phase 1